RAKEIORA

Full title: Rakeiora Cancer Genomic Medicine Research Pathfinder Study: A pathfinder program to develop and test infrastructure for genomic medicine research in Aotearoa New Zealand.
Cancer type: All cancers including blood cancers
Status: No longer recruiting

Brief description:

 

The aim of the Rakeiora Study is to develop an initial, proof-of-concept, cancer genomic research infrastructure that will be the foundation for a scalable national cancer genomics research infrastructure.

Objectives:

  1. To establish protocols and processes for managing genomic medicine research data, co-designed and co-led with/by Māori.
  2. To design a prototype cancer genomic medicine research information technology (IT) platform.
  3. Using genomic and health information from participants, test the prototype cancer genomic research infrastructure and demonstrate ability to: link genomic data with health data, usefulness across a range of research problems, alignment with Māori values including data sovereignty, researcher credentialing and research project governance, security, privacy and scalability.

This study plans to recruit 100 participants with any type of cancer. A cancer tissue sample (stored tissue sample or blood sample) and a normal tissue sample (blood sample or nail clipping/cheek swab) will be collected from each participant.

Sites: Auckland
Lead Investigator: Professor Cris Print (University of Auckland), Dr Helen Wihongi (Auckland & Waitematā DHB)
Contact: Jade Scott (j.scott@auckland.ac.nz)
Sponsor: University of Auckland
Funder: Ministry of Business, Innovation & Employment (MBIE) through Genomics Aotearoa (GA)
Trial Registry reference: Universal Trial Number (UTN): U1111-1274
Ethics number: 2022 EXP 11206
Publications: None currently

 

Rakeiora Study Advertisement